THERAPY DOSSIER · th-62393a62e690

FTP nanoparticles (Pluronic F-127, tannic acid and biguanide-based polymetformin)

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Wound
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 31934739 ↗2020Reported benefit

Biguanide-Derived Polymeric Nanoparticles Kill MRSA Biofilm and Suppress Infection.

MouseWoundBALB/c and C57BL/6Male and femaleApplication to the infected wound; intravenous injection for toxicity assessment8 to 32 ug/mL in vitro; 10 mg/kg intravenously in the acute…

Model: Murine excisional skin wound infected with methicillin-resistant Staphylococcus aureus USA300 biofilm

FTP nanoparticles reduced biofilm bacterial counts by about 100-fold more than polymetformin in vitro and achieved a 1.8 log reduction of biofilm-associated MRSA USA300 in the murine excisional wound, outperforming vancomycin (0.8 log reduction), with lower cytotoxicity than polymetformin and no ac…

Extraction: extract · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.

Loading the evidence…